Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Aaron Gal is an analyst at Bernstein. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/26/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10/17/2024 | GILD | Buy Now | Gilead Sciences | $108.00 | -2.78% | Aaron Gal54% | → $105 | Initiates | → Outperform | Get Alert |
| 10/17/2024 | ABBV | Buy Now | AbbVie | $201.50 | 0.74% | Aaron Gal54% | → $203 | Initiates | → Market Perform | Get Alert |
| 10/17/2024 | AMGN | Buy Now | Amgen | $306.94 | 23.8% | Aaron Gal54% | → $380 | Initiates | → Outperform | Get Alert |
| 03/11/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $633.16 | 77.68% | Aaron Gal54% | → $1125 | Initiates | → Outperform | Get Alert |
| 01/03/2022 | ABBV | Buy Now | AbbVie | $201.50 | -23.08% | Aaron Gal54% | $130 → $155 | Maintains | Outperform | Get Alert |
| 01/03/2022 | REGN | Buy Now | Regeneron Pharmaceuticals | $633.16 | 4.24% | Aaron Gal54% | → $660 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/15/2021 | REGN | Buy Now | Regeneron Pharmaceuticals | $633.16 | 4.24% | Aaron Gal54% | → $660 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/11/2021 | BIIB | Buy Now | Biogen | $139.16 | 259.3% | Aaron Gal54% | → $500 | Upgrade | Market Perform → Outperform | Get Alert |
| 04/01/2021 | GILD | Buy Now | Gilead Sciences | $108.00 | -25.93% | Aaron Gal54% | → $80 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/14/2020 | VTRS | Buy Now | Viatris | $8.98 | 133.87% | Aaron Gal54% | → $21 | Initiates | → Market Perform | Get Alert |
| 10/09/2020 | AMGN | Buy Now | Amgen | $306.94 | — | Aaron Gal54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/09/2020 | BIIB | Buy Now | Biogen | $139.16 | 113.42% | Aaron Gal54% | $360 → $297 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/06/2020 | GILD | Buy Now | Gilead Sciences | $108.00 | -35.19% | Aaron Gal54% | $78 → $70 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/30/2019 | BIIB | Buy Now | Biogen | $139.16 | — | Aaron Gal54% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 04/26/2019 | GILD | Buy Now | Gilead Sciences | $108.00 | — | Aaron Gal54% | — | Initiates | → Outperform | Get Alert |
| 04/26/2019 | GILD | Buy Now | Gilead Sciences | $108.00 | -24.07% | Aaron Gal54% | → $82 | Initiates | → Outperform | Get Alert |
| 04/01/2019 | CELG | Buy Now | Celgene | — | — | Aaron Gal54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/19/2018 | BIIB | Buy Now | Biogen | $139.16 | — | Aaron Gal54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/23/2018 | CELG | Buy Now | Celgene | — | — | Aaron Gal54% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 12/27/2017 | CELG | Buy Now | Celgene | — | — | Aaron Gal54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/17/2017 | CELG | Buy Now | Celgene | — | — | Aaron Gal54% | → $162 | Initiates | → Outperform | Get Alert |
| 08/04/2017 | TEVA | Buy Now | Teva Pharmaceutical Indus | $15.73 | — | Aaron Gal54% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/29/2016 | AMGN | Buy Now | Amgen | $306.94 | — | Aaron Gal54% | — | Initiates | → Market Perform | Get Alert |
| 06/29/2016 | BIIB | Buy Now | Biogen | $139.16 | — | Aaron Gal54% | — | Initiates | → Outperform | Get Alert |
| 07/27/2015 | BIIB | Buy Now | Biogen | $139.16 | 176.66% | Aaron Gal54% | $436 → $385 | Upgrade | Market Perform → Outperform | Get Alert |
| 10/01/2012 | GILD | Buy Now | Gilead Sciences | $108.00 | — | Aaron Gal54% | — | Upgrade | Market Perform → Outperform | Get Alert |
